Skip to main content
Caplight Logo









AffyImmune Therapeutics

AffyImmune Therapeutics

Private
Natick, MassachusettsHealthcare & Life Scienceshttps://affyimmune.com

Last Round

Series A

Oct 7, 2021

Total Funding Raised

$38.55M

Company Overview

AffyImmune Therapeutics is a biotechnology company that develops affinity-tuned CAR T cell therapies for the treatment of solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T cell therapysolid tumor treatmentaffinity-tuned receptorcell therapyoncologybiotechnologyclinical-stage biotechanaplastic thyroid cancercancer immunotherapyprecision medicinedrug developmentnext-gen CAR-T

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AffyImmune Therapeutics Comparables

Compare AffyImmune Therapeutics with similar companies based on industry and business-model similarity.

AffyImmune Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Innovative Cellular Therapeutics
87%
Bio4t2
87%
Leucid Bio
85%

AffyImmune Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 7, 2021
GrantMay 25, 2021
Series ANov 28, 2018

Key People

Founding team and executive leadership

Daniel Janse

Chief Executive Officer

Executive Team

AffyImmune Therapeutics Investors

Notable investors and investment history

AffyImmune Therapeutics investors
InvestorRounds
National Cancer InstituteGrant
Cornell University Office of University InvestmentsSeries A
ORI CapitalSeries A

AffyImmune Therapeutics Filings

Explore SEC and related filing metadata, where available.

AffyImmune Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AffyImmune Therapeutics's valuation, stock price, and market status.

Is AffyImmune Therapeutics a public or private company?

AffyImmune Therapeutics is a private company.

What is the current stock price of AffyImmune Therapeutics?

AffyImmune Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is AffyImmune Therapeutics worth (valuation)?

Valuation information for AffyImmune Therapeutics is not publicly available.

Can I buy AffyImmune Therapeutics stock?

AffyImmune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AffyImmune Therapeutics's last funding round?

AffyImmune Therapeutics's most recent funding round was Series A Extension on October 7, 2021.

Who are the main investors in AffyImmune Therapeutics?

Key investors in AffyImmune Therapeutics include ORI Capital.

Will AffyImmune Therapeutics IPO soon?

No public IPO plans have been announced for AffyImmune Therapeutics.

How can I track AffyImmune Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AffyImmune Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNatick, Massachusetts
Employee Range7
Year Founded2016
Last FundingOct 7, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?